Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04404569 · ClinicalTrials.gov registry record · Phase 1
Continued Treatment for Participants Enrolled in Studies of BXQ-350
A Phase 1 study, sponsored by Bexion Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT04404569 is a Phase 1 study that was terminated before completion, run by Bexion Pharmaceuticals. The registered enrollment target is 5 participants.
The verdict
NCT04404569, a Phase 1 study, was terminated before completion, sponsored by Bexion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a study to allow continued treatment for participants enrolled in studies of BXQ-350. This study is intended only for those who have completed the required study observation period or are still on treatment upon the closure of their respective BXQ-350 clinical study. The additional treatment is optional and voluntary.
Interventions
- DRUG BXQ-350
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-06-08 |
| Est. Completion | 2024-09-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04404569
The ClinicalTrials.gov registry entry for NCT04404569 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bexion Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BXQ-350 is the first listed.
NCT04404569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04404569 about?
NCT04404569 is a clinical study titled "Continued Treatment for Participants Enrolled in Studies of BXQ-350". This is a study to allow continued treatment for participants enrolled in studies of BXQ-350. This study is intended only for those who have completed the required study observation period or are still on treatment upon the closure of their respective BXQ-350 clinical study. The additional treatment...
What is the current status of trial NCT04404569?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2020-06-08. Estimated completion is 2024-09-23.
What interventions are being tested in trial NCT04404569?
The interventions under investigation include: BXQ-350 (DRUG).
Who is sponsoring clinical trial NCT04404569?
This trial is sponsored by Bexion Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.